MXC: $0.027
Who

MGC Pharmaceuticals Limited (‘MGC’) (ASX: MXC) is a biopharma company with a “Nature to Medicine” strategy at the forefront of the emerging phytocannabinoid and plant derived medicine markets. The company’s mission is to build an innovative, global bio-pharma company providing standardised, affordable plant derived medicines of the highest regulatory compliance for targeted global markets.

Read More
What

MGC currently holds pipelines for phytocannabinoid-based medications and unique formulations (Phytomedicines), both proprietary and for third parties, all under GMP certified regulations and facilities. This includes our ability to create API (Active Pharmaceutical Ingredient) of various phytocannabinoids alongside compounding to be used in the pharmaceutical treatment and research globally. MGC has developed an efficient production pipeline of phytocannabinoid derived medications, with multiple products currently being prescribed to patients, and products in clinical development and testing.

Read More
Why

We’re devoted to providing value to shareholders and providing you with the latest company information. This comprises of ASX announcements, financial reports, and other significant updates. You can also access FAQs and see the latest share price information here. MGC Pharmaceuticals trades on the Australian Securities Exchange (ASX) under the ASX code MXC.

Read More
Latest ASX Announcements
13/1/21Key Appointment - Global Chief Sales Officer 22/12/20Appendix 2A 22/12/20MGC Pharma to receive grant for Malta production facility 15/12/20ArtemiC Phase II Clinical Trial Results
Read More
Research Reports

18/2/20The Green Fund Research Report 9/10/19Alacrita Market Projections Report 11/7/19Edison Report 24/5/19Research Publication on the Effectiveness of Cannabinoids on Glioblastoma
Read More Research Reports
Investor Information

Sign up to MGC Pharma’s Investor Information to receive the latest news, updates, announcements and investor presentations, straight to your inbox.


MGC Pharmaceuticals partners and collaborates with academia, worldwide prominent universities and companies all over the world to conduct extensive research and develop the highest quality products for our patients.

Distributors

Education and Patient Access Partners

Research and Academia

ASX: MXC
$0.027
Sunday, 17 January 2021
Latest Announcements
13/1/21Key Appointment - Global Chief Sales Officer 22/12/20Appendix 2A 22/12/20MGC Pharma to receive grant for Malta production facility 15/12/20ArtemiC Phase II Clinical Trial Results 11/12/20Appendix 2A 9/12/20Completion of Unmarketable Parcel Share Sale Facility 7/12/20ArtemiC Phase II Clinical Trial Results Update

Australia
Pharma Corporate & Financial Headquarters
Slovenia
Pharma European Operational Headquarters
UK
European Corporate Headquarters
Who
What
Why
Contact Us